EMCDDA Home
  • EN
Search

Country overview: Norway

Key statistics on the drug situation in Norway

  Indicator Year (0)   Country
data
EU range  
Min. Max.
Lifetime prevalence of drug use among young adults (15 to 34 years old) cannabis GPS 2009   21.9 % 2.9 % 45.5 % 1
Lifetime prevalence of drug use among all adults (15 to 64 years old) cannabis 2009   14.6 % 1.5 % 32.5 % 1
Last year prevalence of drug use among young adults (15 to 34 years old) cannabis 2009   7 % 0.9 % 21.6 % 1
Last year prevalence of drug use among all adults (15 to 64 years old) cannabis 2009   3.8 % 0.4 % 14.3 % 1
Lifetime prevalence of drug use among young adults (15 to 34 years old) cocaine 2009   4.2 % 0.1 % 13.6 % 1
Lifetime prevalence of drug use among all adults (15 to 64 years old) cocaine 2009   2.5 % 0.1 % 10.2 % 1
Last year prevalence of drug use among young adults (15 to 34 years old) cocaine 2009   0.6 % 0.1 % 4.8 % 1
Last year prevalence of drug use among all adults (15 to 64 years old) cocaine 2009   0.4 % 0 % 2.7 % 1
Recent school surveys: lifetime prevalence (15 to 16 years old) cannabis EYE 2007   6 % 4 % 45 % 2
Recent school surveys: lifetime prevalence (15 to 16 years old) cocaine 2007   1 % 1 % 5 % 2
Problem drug use rate per 1 000 population aged 15 to 64 years old PDU 2008   3 0.5 10.1 1
Injecting drug use rate per 1 000 population aged 15 to 64 years old 2008   3.2 0.22 15.1 1
Infectious diseases (% infected) HIV INF 2009
2.4 % 0 % 32.5 % 1
Infectious diseases (cases per million) HIV infections newly diagnosed in injecting drug users 2009   2.3 0 63.4 5
Infectious diseases (% infected) HCV 2009
72.9 % 22.4 % 90.7 % 1
Infectious diseases (% infected) HBV HBsAg 2009 a 0 % 0.5 % 3.9 % 1
Drug-related deaths DRD 2008   263 6 2 481 3
Drug law offences (as number of reports of offences) DLO 2009 b 39 280 772 397 620 2
Drug law offences for use/possession 2009   19 140 285 372 230 1
Cannabis drug law offences i       24.4 % 91.5 % 4
Number of new clients entering treatment TDI       21 45 048 3
Number of new clients entering treatment with known primary drug       0 43 683 3
New clients entering treatment (% opioids of clients with known primary drug)       3.1 % 92.8 % 3
New clients entering treatment (% cocaine of clients with known primary drug)       0 % 56 % 3
New clients entering treatment (% cannabis of clients with known primary drug)       1.9 % 80.2 % 3
Number of all clients entering treatment       350 139 390 3
Number of all clients entering treatment with known primary drug       350 133 960 3
All clients entering treatment (% opioids of clients with known primary drug)       10.4 % 97.1 % 3
All clients entering treatment (% cocaine of clients with known primary drug)       0.1 % 46.4 % 3
All clients entering treatment (% cannabis of clients with known primary drug)       0.6 % 69.8 % 3
Syringes provided through needle and syringe programmes HSR 2009 c 3 099 790 0 4 861 195 1
Number of all clients in substitution treatment 2009   5 383 189 137 541 2
Price in euros per gram cannabis herb ii PPP 2009 d EUR 12.50–18.80 EUR 2 EUR 70 5
Price in euros per gram cannabis resin ii 2009 d EUR 12.50–12.50 EUR 3 EUR 19 5
Price in euros per gram cocaine ii 2009 d EUR 87.50–125 EUR 45 EUR 104 5
Price in euros per gram heroin (brown) ii;iv 2009 d EUR 87.50–100 EUR 23 EUR 135 5
Price in euros 1 tablet XTC ii 2009 d EUR 12.50–12.50 EUR 3 EUR 15.90 5
Price in euros per gram amphetamine ii 2009 d EUR 25–50 EUR 8 EUR 41.80 5
Purity (%) cocaine iii 2009   25 % 18 % 51.3 % 5
Purity (%) heroin (brown) iii 2009   25 % 12.9 % 37 % 5
Potency (%) cannabis resin iii;v 2009   14 % 2.9 % 17.3 % 5
Potency (%) cannabis herb iii 2009   3.8 % 1.3 % 12.4 % 5

Notes

i As percentage of all drug law offences reported.

ii When available, country provides minimum, maximum, mean, median and modal (most frequent) price in euros recorded. This table shows the mean price in euros.

iii When available, country provides minimum, maximum, mean, median and modal (most frequent) purity/potency (percentage). This table shows the mean purity/potency (percentage).

iv The minimum value in the European range refers to the mean price.

v The maximum value in the European range refers to the mean potency.

0 Most recent available data shown. Any data prior to 2005 not shown.

1 2005 to 2009 data.

2 2007 to 2009 data.

3 2008 to 2009 data.

4 2006 to 2009 data.

5 2009 data.

a Data are not national. Based on a sample from Oslo.

b Persons.

c Data on number of syringes are partial, based on the reports from 11 out of 26 municipalities.

d Values are minimum price recorded and maximum price recorded and not the mean.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>

Contact us

EMCDDA
Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Monday, 14 November 2011